InMode Ltd. (INMD)
NASDAQ: INMD · Real-Time Price · USD
13.74
+0.08 (0.59%)
At close: Aug 1, 2025, 4:00 PM
13.88
+0.14 (1.02%)
After-hours: Aug 1, 2025, 7:51 PM EDT
CTI BioPharma Revenue
InMode had revenue of $95.60M in the quarter ending June 30, 2025, with 10.59% growth. This brings the company's revenue in the last twelve months to $401.56M, down -3.62% year-over-year. In the year 2024, InMode had annual revenue of $394.82M, down -19.76%.
Revenue (ttm)
$401.56M
Revenue Growth
-3.62%
P/S Ratio
2.40
Revenue / Employee
$670,386
Employees
599
Market Cap
868.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 394.82M | -97.23M | -19.76% |
| Dec 31, 2023 | 492.05M | 37.78M | 8.32% |
| Dec 31, 2022 | 454.27M | 96.71M | 27.05% |
| Dec 31, 2021 | 357.57M | 151.46M | 73.49% |
| Dec 31, 2020 | 206.11M | 49.75M | 31.81% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 57.37B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
INMD News
- 2 days ago - InMode Ltd. (INMD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - InMode Reports Second Quarter 2025 Financial Results: Quarterly Revenue of $95.6 Million, 80% Gross Margins - PRNewsWire
- 20 days ago - InMode: Margin Pressure, But Optionality Makes It Worth A Look - Seeking Alpha
- 22 days ago - InMode to Report Second Quarter 2025 Financial Results and Hold Conference Call on July 30, Expects Q2 Revenue Between $95.4M-$95.5M, Decreases Full Year 2025 Revenue Guidance to be Between $365M-$375M - PRNewsWire
- 2 months ago - InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025 - PRNewsWire
- 3 months ago - DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program - PRNewsWire
- 3 months ago - InMode to Present at Upcoming Investor Conferences and Events - PRNewsWire
- 3 months ago - InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges - PRNewsWire